Aberdeen Group plc Grows Holdings in Xencor, Inc. $XNCR

Key Points

• Aberdeen Group plc increased its holdings in Xencor, Inc. by 114.9%, owning 377,112 shares valued at $4,012,000 as of the last quarter.
• Xencor reported a quarterly earnings per share of ($0.41), exceeding analysts' expectations of ($0.78) and showing significant revenue growth of 82.4% year-over-year.
• Analyst ratings for Xencor are mixed, with seven analysts rating it a Buy and Barclays setting a notably low target price of $6.00, while the average target remains around $26.43.

Aberdeen Group plc boosted its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 114.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 377,112 shares of the biopharmaceutical company's stock after buying an additional 201,592 shares during the quarter. Aberdeen Group plc owned 0.53% of Xencor worth $4,012,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its stake in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Xencor in the fourth quarter valued at about $34,000. CWM LLC grew its stake in Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in Xencor during the 4th quarter worth approximately $101,000. Finally, Summit Investment Advisors Inc. increased its holdings in Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock worth $162,000 after purchasing an additional 1,282 shares during the last quarter.

Xencor Stock Down 1.1%

Shares of XNCR stock opened at $7.51 on Thursday. The business has a 50 day moving average of $8.40 and a two-hundred day moving average of $10.35. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $27.24. The company has a market cap of $535.61 million, a P/E ratio of -3.13 and a beta of 0.89.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business had revenue of $43.61 million for the quarter, compared to analysts' expectations of $22.59 million. During the same period in the prior year, the firm earned ($1.07) EPS. The business's quarterly revenue was up 82.4% on a year-over-year basis. Analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on XNCR. Wedbush decreased their price target on shares of Xencor from $31.00 to $26.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Wells Fargo & Company decreased their price objective on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Finally, Barclays dropped their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Xencor currently has an average rating of "Moderate Buy" and a consensus price target of $26.43.

Insider Buying and Selling at Xencor

In other Xencor news, Director Richard J. Ranieri sold 2,993 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. The trade was a 13.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the transaction, the director owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,194 shares of company stock worth $103,209. 4.76% of the stock is owned by insiders.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.